Alex Niu
YOU?
Author Swipe
View article: A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study
A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study Open
Introduction: NAVD has become a standard-of-care for frontline (1L) treatment (tx) of advanced stage cHL, based on the results of the S1826 study. S1826 demonstrated a 1-year progression free survival (PFS) of 94% for NAVD compared to 86% …
View article: Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola R+CHP) results in similar clinical outcomes than rituximab and dose adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R+DA-EPOCH) in patients with high-risk features diffuse large B-cell lymphoma (DLBCL): A single institution experience.
Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola R+CHP) results in similar clinical outcomes than rituximab and dose adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R+DA-EPOCH) in patients with high-risk features diffuse large B-cell lymphoma (DLBCL): A single institution experience. Open
Background: DLBCL is the most prevalent aggressive form of B-cell lymphoma. Modern molecular profiling subdivides DLBCL into biological distinct subtypes, and the combination of staging, immunohistochemistry (IHC), and cytogenetic studies …
View article: CRISPR-based assay reveals SARS-CoV-2 RNA dynamic changes and redistribution patterns in non-human primate model
CRISPR-based assay reveals SARS-CoV-2 RNA dynamic changes and redistribution patterns in non-human primate model Open
Mounting evidence indicates that SARS-CoV-2 can infect multiple systemic tissues, but few studies have evaluated SARS-CoV-2 RNA dynamics in multiple specimen types due to their reduced accessibility and diminished performance of RT-qPCR wi…
View article: Liposome-mediated detection of SARS-CoV-2 RNA-positive extracellular vesicles in plasma
Liposome-mediated detection of SARS-CoV-2 RNA-positive extracellular vesicles in plasma Open
View article: High mortality with High false negative rate: COVID-19 infection in patients with hematologic malignancies
High mortality with High false negative rate: COVID-19 infection in patients with hematologic malignancies Open
View article: Sensitive tracking of circulating viral RNA through all stages of SARS-CoV-2 infection
Sensitive tracking of circulating viral RNA through all stages of SARS-CoV-2 infection Open
To improve diagnostic sensitivity detection of SARS-CoV-2 RNA in blood by a CRISPR-augmented RT-PCR assay.
View article: Reinfection versus failure of viral clearance in a COVID-19 patient with hematologic malignancy
Reinfection versus failure of viral clearance in a COVID-19 patient with hematologic malignancy Open
View article: A smartphone-read ultrasensitive and quantitative saliva test for COVID-19
A smartphone-read ultrasensitive and quantitative saliva test for COVID-19 Open
An isolation-free smartphone-based saliva assay can diagnose COVID-19 cases and quantify viral load within 15 min.
View article: COVID-19 Convalescent Plasma Decreased Oxygen Requirement and Hospital Stay in COVID-19 Hospitalized Patients Including Those with Hematological Malignancies: A Report of 16 Patients
COVID-19 Convalescent Plasma Decreased Oxygen Requirement and Hospital Stay in COVID-19 Hospitalized Patients Including Those with Hematological Malignancies: A Report of 16 Patients Open
Introduction In the absence of effective and readily available therapy for COVID-19, immediate interventions to improve its mortality are a public health emergency. COVID-19 convalescent plasma (CCP) carries antibodies against SARS-CoV-2 a…
View article: COVID-19 in Patients with Hematological Malignancies: High False Negative Rate with High Mortality
COVID-19 in Patients with Hematological Malignancies: High False Negative Rate with High Mortality Open
Introduction Patients with hematological malignancies (HM) are uniquely immunocompromised and considered at high risk for COVID-19. However, data regarding the diagnosis, clinical course, treatment, and outcomes of these patients is sparse…
View article: COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma
COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma Open
View article: Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer
Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer Open
While lack of AR alterations in ctDNA was associated with more favorable outcomes, the present dataset is insufficient to recommend the use of ctDNA to impact clinical decision-making in this setting. Further understanding of the implicati…